Journals / Eurasian Journal of Biological and Chemical Sciences / 2021 / Cilt: 4 - Sayı: 2

Development of a Liquid Chromatographic Method for Apomorphine Hydrochloride Quantitation in the Active Pharmaceutical Ingredients and in the Dosage Forms

Pages
44–50
Publication Date
2021-12-26
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It has been found that the developed method is sensitive (Detection and quantification limits were determined as 1.3 μg mL-1 and 3.8 μg mL-1, respectively), precise (RSD

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Apomorphine is currently used as a dopamine agonist to treat advanced Parkinson Disease.
📊
Key Findings & Data:C18 column was used for separation.
💡
Conclusion & Impact:It has been found that the developed method is sensitive (Detection and quantification limits were determined as 1.3 μg mL-1 and 3.8 μg mL-1, respectively), precise (RSD
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Apomorphine · HPLC · Pharmaceuticals

Abstract

Apomorphine is currently used as a dopamine agonist to treat advanced Parkinson Disease. In the present study, we developed a sensitive, simple, reliable, and robust HPLC method for quality control of apomorphine hydrochloride in bulk drug and pharmaceutical formulations. C18 column was used for separation. Isocratic elution was performed using mobile phase A: 50 mM potassium dihydrogen phosphate solution (pH:3 with ortho-phosphoric acid), B: acetonitrile in the ratio of 85:15 (A: B), and the mobile-phase flow rate was kept at 1 mL min-1. Analyses were carried out at 272 nm using a UV detector. A perfect linear relationship between peak-area versus drug concentration in the range of 10‑100 μg mL-1 was observed (r2, 0.9999). It has been found that the developed method is sensitive (Detection and quantification limits were determined as 1.3 μg mL-1 and 3.8 μg mL-1, respectively), precise (RSD

🔖

Cite This Article

AYDIN, B. S., BULDUK, İ. (2021). Development of a Liquid Chromatographic Method for Apomorphine Hydrochloride Quantitation in the Active Pharmaceutical Ingredients and in the Dosage Forms. Eurasian Journal of Biological and Chemical Sciences, Cilt: 4 - Sayı: 2, 44–50. https://ajindex.com/articles/755953

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Referans1 Tysnes OB, Storstein A. 2017 Epidemiology of Parkinson’s disease. J Neural Transm. 124(8). 901–905. Referans2 Poewe W, Seppi K, Tanner CM, et al. 2017. Parkinson disease. Nat Rev Dis Primers. 3. 17013-17018 Referans3 Kempster PA, Frankel JP, Stern GM, Lees AJ. 1990. Comparison of motor response to apomorphine and levodopa in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 53(11).1004–1007. Referans4 Poewe WH, Lees AJ, Stern GM. 1986. Low-dose L-dopa therapy in Parkinson’s disease: a 6-year follow-up study. Neurology. 36(11).1528–1530. Referans5 Sweet RD, McDowell FH. 1975. Five years’ treatment of Parkinson’s disease with levodopa. Therapeutic results and survival of 100 patients. Ann Intern Med. 83(4). 456–463. Referans6 Ernst AM, Smelik PG. 1966. Site of action of dopamine and apomorphine on compulsive gnawing behavior in rats. Experientia. 22(12). 837–8. Referans7 Auffret M, Drapier S, Vérin M. 2018. Pharmacological insights into the use of apomorphine in parkinson’s disease: clinical relevance. Clin Drug Investig. 38(4). 287–312. Referans8 Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin J-A, Newman- Tancredi A. 2002. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 303(2). 791–804. Referans9 Jenner P, Katzenschlager R. 2016. Apomorphine pharmacological properties and clinical trials in Parkinson’s disease. Park Relat Disord. 33. 13–21. Referans10 Le Witt PA, Ondo WG, Van Lunen B, Bottini PB. 2009. Open-label study assessment of safety and adverse effects of subcutaneous apomorphine injections in treating ‘off’ episodes in advanced Parkinson disease. Clin Neuropharmacol. 32(2). 89–93. Referans11 Arppe AE. 1845. Ueber eine merkwürdige Veränderung des Morphins durch Schwefelsäure. Ann der Chemie und Pharm. 55(1). 96–101. Referans12 Matthiessen A, Wright CRA. 1868. Researches into the Chemical constitution of the opium bases. Part I. on the action of hydrochloric acid on morphia. Proc R Soc Lond. (1868) 17. 455–60 Referans13 Taba P, Lees A, Stern G. 2013. Erich Harnack (1852-1915) and a short history of apomorphine. Eur Neurol. 69(6). 321–4. Refereans14 Pierce FM. 1870. Notes on Apomorphia. British Medical Jornal. 1(478). 204. Referans15 Hare F. 1912. On alcoholism its clinical aspects and treatment. London: J&A Churchill. Referans16 Gee S. 1869. On the action of a